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Extracellular matrix (ECM) remodeling is important during bone development and repair. Because matrix metalloproteinase 13
(MMP13,collagenase-3)playsaroleinlongbonedevelopment,wehaveexamineditsroleduringadultskeletalrepair.Inthisstudy
we find that MMP13 is expressed by hypertrophic chondrocytes and osteoblasts in the fracture callus. We demonstrate that
MMP13 is required for proper resorption of hypertrophic cartilage and for normal bone remodeling during non-stabilized fracture
healing, which occurs via endochondral ossification. However, no difference in callus strength was detected in the absence of
MMP13. Transplant of wild-type bone marrow, which reconstitutes cells only of the hematopoietic lineage, did not rescue the
endochondral repair defect, indicating that impaired healing in Mmp13
2/2 mice is intrinsic to cartilage and bone. Mmp13
2/2 mice
also exhibited altered bone remodeling during healing of stabilized fractures and cortical defects via intramembranous
ossification. This indicates that the bone phenotype occurs independently from the cartilage phenotype. Taken together, our
findings demonstrate that MMP13 is involved in normal remodeling of bone and cartilage during adult skeletal repair, and that
MMP13 may act directly in the initial stages of ECM degradation in these tissues prior to invasion of blood vessels and osteoclasts.
Citation: Behonick DJ, Xing Z, Lieu S, Buckley JM, Lotz JC, et al (2007) Role of Matrix Metalloproteinase 13 in Both Endochondral and
Intramembranous Ossification during Skeletal Regeneration. PLoS ONE 2(11): e1150. doi:10.1371/journal.pone.0001150
INTRODUCTION
Bone is noteworthy in that it does not heal through the formation of
scar tissue, but rather through a regenerative process that resembles
fetal skeletal development. During bone healing much of the initial
developmental program is conserved, from the various cell types
involvedto the geneticmechanismsregulating celldifferentiation[1–
3]. As in development, repair of long bones by endochondral
ossification begins with the production of cartilage at the injury site.
The chondrocytes of the fracture callus deposit an extracellular
matrix (ECM) comprised of type II collagen (Col2) and aggrecan,
then differentiate into hypertrophic chondrocytes that deposit an
ECM comprised of type X collagen (Col10). This ECM is then
partially mineralized, resorbed and replaced by a matrix comprised
predominantly of type I collagen (Col1). This process is regulated by
the action of invading osteoblasts and osteoclasts. These cells, whose
development andfunctionareintimatelylinked,continuetoremodel
this regenerated tissue into mature bone until the fracture is
consolidated. Other aspects of skeletal repair differ from skeletal
development. For example, skeletal repair may be influenced by the
mechanical environment. While non-stabilized fractures heal via
endochondral ossification, stabilized fractures heal via intramem-
branous ossification. In this process, mesenchymal precursors
recruited to the site of injury differentiate only along the osteoblastic
lineage and produce both compact (cortical) and spongy (cancellous)
bone in the absence of cartilage production [4,5].
Skeletal elements are rich in ECM and the remodeling of this
ECM is central to both development and repair [3,5]. Matrix
remodeling in both of these processes is regulated by many of the
same proteases, and these enzymes may determine the rate and
effectiveness of the development and repair programs [6]. The role
of matrix metalloproteinases (MMPs) during bone development
has been studied extensively [7–12]. MMP13 promotes both the
resorption of hypertrophic cartilage from the growth plate and the
remodeling of newly deposited trabecular bone during long bone
development [9,10]. Moreover, other work has pointed to the
requirement for MMPs used in bone development for bone repair
[3,5,13,14]. These reports have led us to ask whether MMP13 also
participates in skeletal repair. In the present study, we employed
several models of repair by both endochondral and intramem-
branous ossification, including non-stabilized and stabilized
fracture models as well as a cortical defect model, to elucidate
the role of MMP13 during the various stages of healing.
RESULTS
Mmp13 is expressed in the non-stabilized fracture
callus
We first established which cells express Mmp13 during endochon-
dral ossification in non-stabilized fractures. We performed in situ
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calluses from wild-type (WT) mice using probes for Mmp13 and
a number of cell type-specific marker genes (Fig. 1). At 3 days post-
fracture, we observed Mmp13 expression in regions of activated
periosteum that also expressed Col1 (data not shown). Likewise, at
6 days post-fracture, we observed Mmp13-expressing cells within
the Col1 expression domain in Osteocalcin (Oc)-negative portions of
the periosteum, indicating that Mmp13 is expressed during the
early stages of healing by immature osteoblasts (Fig. 1A–D and
data not shown). The Mmp13 expression pattern differed from that
of Mmp9, indicating that Mmp13 was not upregulated in newly
recruited inflammatory cells and osteoclasts (Fig. 1B–D) as
observed previously (Colnot et al., 2003). At 10 days post-fracture,
Mmp13 expression in the cartilage overlapped with Col10 and
Vascular endothelial growth factor (Vegf) expression, indicating that
Mmp13 is expressed by hypertrophic and late hypertrophic
chondrocytes (Fig. 1E–H). At 14 days post-fracture, Mmp13
expression colocalized with Col1 and Oc expression, suggesting
that by this time point Mmp13 is expressed in both immature and
mature osteoblasts within the callus (Fig. 1I–L). Mmp13 expression
was detected in osteoblasts throughout the remodeling phase of
healing and was not associated with osteoclasts (Fig. 1A–D and
data not shown). These results demonstrate that the expression
pattern of Mmp13 in both cartilage and bone tissues during
fracture healing parallels that seen during development via
endochondral ossification [10,15,16] and suggest that MMP13
may play a role in both cartilaginous and bony tissues during
fracture healing.
Mmp13
2/2 mice accumulate cartilage during non-
stabilized fracture healing but cartilage
differentiation to hypertrophy is normal
Cartilage begins to develop in the non-stabilized fracture callus by
days 3 to 7 post-fracture (soft callus phase), peaks at day 10, is being
remodeled by day 14 (hard callus phase) and is fully resorbed by day
28 (remodeling phase; [5]). To study the effect of MMP13 deficiency
on this process, we created closed, non-stabilized fractures in WT and
Mmp13
2/2 adult mice and examined the timing and extent of
cartilage and bone formation throughout the healing process. Histo-
logical analyses indicated that cartilage is formed in Mmp13
2/2
calluses, but its remodeling and removal are delayed (Fig 2A).
Quantitative analyses confirmed these observations. Histomorpho-
metric analyses revealed that there was no significant difference in
total callus volume between WT and Mmp13
2/2 samples at any time
point examined (Fig. 2B), but there was a significantlygreater volume
of cartilage and of cartilage as a proportion of total callus volume in
Mmp13
2/2 calluses at 7, 14 and 21 days post-fracture (Fig. 2B).
Examination of the percentage of samples that exhibited cartilage
confirmed the delay in cartilage removal in Mmp13
2/2 calluses. At
day 21, all Mmp13
2/2 calluses contained cartilage while only one
third of WT calluses did. At day 28, cartilage was still present in one
third of Mmp13
2/2 calluses but was never observed in WT samples.
To characterize the differences observed during the early stages
of healing, we analyzed Col2 expression in fracture calluses at day
5 by in situ hybridization. We did not detect an alteration in the
initial differentiation of chondrocytes in Mmp13
2/2 calluses as
Figure 1. Mmp13 expression during non-stabilized fracture healing. (Left column) Safranin-O/Fast Green (SO) and Trichrome (TC) stained sagittal
sections through the WT callus at 6 (A), 10 (E) and 14 (I) days post-fracture. Cartilage (red) develops during the soft callus phase of healing (A), is
resorbed during the hard callus phase (E) and is replaced by bone (blue, I). (Middle/Right column) In situ hybridization analyses of Mmp13 expression
and osteoblast/chondrocyte differentiation markers. (B–D) At 6 days post-fracture, Mmp13 is expressed in the callus and overlaps with Col1-
expressing cells (early osteoblasts) but not Mmp9-expressing cells (osteoclasts and inflammatory cells). (F–H) At day 10, Mmp13 mRNA is detected in
hypertrophic chondrocytes also expressing Col10 and Vegf.( J–L) At day 14, Mmp13 is expressed in mature osteoblasts co-expressing Col1 and/or Oc.
Scale bars: A, E, I=1mm; B-D, F-H, J-L-200 mm.
doi:10.1371/journal.pone.0001150.g001
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cartilage volume observed by day 7 was transient. We next
examined chondrocyte hypertrophy in the Mmp13
2/2 calluses by
investigating Col10 expression (Fig. 3A). The Col10-expression
domain was comparable between WT and Mmp13
2/2 calluses at
days 10 and 14 post-fracture, suggesting that chondrocyte
hypertrophy was not altered in the absence of MMP13. These
studies demonstrate that the absence of MMP13 did not affect the
overall amount of cartilage produced in the callus or its
differentiation to hypertrophy, but did affect the removal of
hypertrophic cartilage.
To understand the basis for the delayed hypertrophic cartilage
removal, we examined angiogenesis and ECM remodeling, two
key components of endochondral ossification (Fig. 3B;
[5,10,12,17]). Platelet endothelial cell adhesion marker (PECAM)
immunostaining (left column) demonstrated that the observed
delay in cartilage remodeling/removal was not due to delayed
vascular invasion into the Mmp13
2/2 callus. Staining for Tartrate-
resistant acid phosphate (TRAP)-positive cells (Fig. 3B, middle
column) demonstrated the delay was also not due to delayed
osteoclast recruitment into the Mmp13
2/2 callus. However, these
recruited blood vessels and osteoclasts did not invade the
hypertrophic cartilage matrix, suggesting the inability of the
cartilage matrix itself to become invaded. We next stained for an
epitope of aggrecan, the major proteoglycan of the cartilage ECM
[18] which is degraded during the very last stages of chondrocyte
differentiation/removal [19]. Cleavage of aggrecan by MMPs,
as assessed by immunostaining for the cryptic DIPEN epitope
of aggrecan (Fig. 3B, right column; [20]), decreased in the
Mmp13
2/2 callus indicating that processing of the cartilage ECM
in the Mmp13
2/2 callus was delayed.
Mmp13
2/2 mice have increased bone density
during non-stabilized fracture healing
Since hypertrophic cartilage remodeling is necessary for the
replacement of cartilage by bone during healing [5], we asked
whether delayed removal of hypertrophic cartilage affects
ossification of the fracture callus in Mmp13
2/2 mice. Histomor-
phometric analyses revealed a significantly smaller bone volume in
Mmp13
2/2 samples at day 7 post-fracture (Fig. 4B), suggesting that
the increase in cartilage formation at this early time point may
have compromised the initial stages of bone formation. By day 14,
however, we did not detect a significantly decreased bone volume
Figure 2. Mmp13
2/2 mice display an accumulation of cartilage during non-stabilized fracture healing. (A) SO staining of WT and Mmp13
2/2
fracture callus at 7, 10, 14, and 21 days post-fracture shows that cartilage persists in the Mmp13
2/2 callus from 14 through 21 days post-fracture.
Scale bar=1 mm (B) Histomorphometric measurements of total callus volume (TV), total cartilage volume (CV) and total cartilage volume as
a proportion of total callus volume (CV/TV) in WT and Mmp13
2/2 mice at day 7 (WT n=6,Mmp13
2/2 n=6), 10 (WT n=8,Mmp13
2/2 n=6), 14 (WT
n=8,Mmp13
2/2 n=6), 21 (WT n=6,Mmp13
2/2 n=6) and 28 (WT n=6,Mmp13
2/2 n=6). There is a statistically significant increase in total cartilage
volume in Mmp13
2/2 calluses compared with WT at day 7 (**p,0.01), 14 (*p,0.05) and 21 (*p,0.05). There is a statistically significant increase in
total cartilage volume as a proportion of total callus volume in Mmp13
2/2 calluses compared with WT at day 7 (**p,0.01), 14 (*p,0.05) and 21
(*p,0.05). Wilcoxon test, bars represent means 6 S.D. At 21 days post-fracture, all Mmp13
2/2 calluses contained cartilage as compared to 1/3 of WT.
At 28 days post-fracture, only Mmp13
2/2 calluses (1/3) still contained cartilage.
doi:10.1371/journal.pone.0001150.g002
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callus volume in Mmp13
2/2 samples compared to WT (Fig. 4B).
This suggests that the increased cartilage deposition/decreased
cartilage removal observed at this time point does not impair new
bone deposition. At later stages of repair, during active remodeling
of the new bone in WT calluses, Mmp13
2/2 calluses had
significantly greater callus bone volume and a significantly greater
bone volume as a proportion of total callus volume, both at days
28 and 56 post-fracture (Fig. 4B).
By histological examination, we observed that spongy bone
accumulated in Mmp13
2/2 calluses while the reconstitution of the
bone marrow cavity was more advanced in WT calluses (Fig. 4A,
day 28, middle column; day 56, right column). Histomorpho-
metric analyses performed on the volumes of new bone in WT and
Mmp13
2/2 calluses at 21 and 28 days post-fracture confirmed
differences in the spongy and compact bone in Mmp13
2/2
calluses. At 28 days post-fracture, there was a significantly greater
volume of spongy bone in Mmp13
2/2 calluses as compared to WT
(Fig. 4C). By contrast, there was no significant difference observed
in compact bone volume, regardless of timepoint or genotype.
Taken together, these results suggest that the increased bone
volume observed in the Mmp13
2/2 non-stabilized fracture callus
resulted from an increase in the spongy bone of the callus.
Furthermore, we performed micro-CT analyses on non-
stabilized fracture calluses from WT and Mmp13
2/2 mice at 21
and 28 days post-fracture. While no difference in overall callus
volume was detected by micro-CT regardless of healing time point
or genotype (data not shown), a significant increase in bone
mineral density was observed in Mmp13
2/2 calluses as compared
to WT at 21 and 28 days post-fracture (Fig. 4D). Given that
histomorphometric analyses indicated no significant increase in
bone volume at 21 days, these results suggest that the bone matrix
Figure 3. Integral steps in endochondral ossification are unperturbed
during non-stabilized fracture repair in Mmp13
2/2 mice. (A) Overlay
of SO stained sections with in situ hybridization for Col2 (red) indicate
no difference in the early differentiation of chondrocytes in WT and
Mmp13
2/2 calluses at day 5. Overlay of SO stained sections with in situ
hybridization for Col10 (yellow) shows a delay in hypertrophic
chondrocyte removal in the Mmp13
2/2 callus at day 14. Scale
bar=1 mm (B) Cellular analyses of WT and Mmp13
2/2 calluses at day
14 show that blood vessels (PECAM) and osteoclasts (TRAP) are present
in the Mmp13
2/2 callus while aggrecan cleavage by MMPs (DIPEN
epitope) is reduced in the Mmp13
2/2 callus. Scale bar=1 mm
doi:10.1371/journal.pone.0001150.g003
Figure 4. Mmp13
2/2 mice display increased bone volume during non-
stabilized fracture healing. (A) Trichrome staining of WT and Mmp13
2/2
non-stabilized fracture calluses shows an increase in the amount of bone
in the Mmp13
2/2 callus compared to WT at days 28 and 56 post-fracture.
Scale bar=1 mm (B) Histomorphometric measurements of total bone
volume (BV) and total bone volume as a proportion of total callus volume
(BV/TV) in WT and Mmp13
2/2 mice at days 7 (WT n=6,Mmp13
2/2 n=6),
10 (WT n=8, Mmp13
2/2 n=6), 14 (WT n=8,Mmp13
2/2 n=6), 21 (WT
n=6,Mmp13
2/2 n=6), 28 (WT n=6,Mmp13
2/2 n=6) and 56 (WT n=5,
Mmp13
2/2n=4)confirmthisobservationThereisastatisticallysignificant
decrease in BV in Mmp13
2/2 calluses compared with WT at day 7
(*p,0.05), but a statistically significant increase in BV and BV/TV in
Mmp13
2/2 calluses compared with WT at days 28 (**p,0.01 and p,0.05
respectively) and 56 (*p,0.05). Wilcoxon test, bars represent means 6
S.D. (C) Histomorphometric measurements indicate a statistically signif-
icant difference in total spongy bone volume in Mmp13
2/2 calluses
compared with WT at day 28 (**p,0.01) but no difference is detected in
total compact bone volume. (D) Micro-CT analyses show that bone
mineral density is significantly increased in the Mmp13
2/2 callus
compared to WT at 21 (**p,0.01) and 28 (*p,0.05) days post-fracture.
Bonferroni corrected t-test, bars represent means 6 SD.
doi:10.1371/journal.pone.0001150.g004
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2/2 calluses at this time point.
By 28 days, the micro-CT results correlated with that of
histomorphometry confirming that MMP13 is required for proper
bone remodeling in the non-stabilized fracture callus.
Since the increase in Mmp13
2/2 callus bone volume observed
by histomorphometry persisted through 8 weeks post-fracture,
these results reflected a prolonged change in the bone volume of
the mutant callus. We considered the possibility that the impact of
MMP13 deficiency on bone volume and bone mineral density in
the non-stabilized fracture callus could affect the mechanical
properties of these calluses. To test this, we performed mechanical
analyses on non-stabilized fracture calluses from WT and
Mmp13
2/2 mice at 14, 21 and 28 days post-fracture (Table 1).
We observed no significant impact on the maximum force at
failure of fracture calluses regardless of healing timepoint or
genotype (Table 1). Therefore, increased bone volume within the
spongy bone compartment of the callus did not change the overall
mechanical properties of the tissue.
WT bone marrow-derived cells do not rescue the
Mmp13
2/2 non-stabilized fracture healing
phenotype
Osteoclasts are the major bone resorbing cells. Although we did
not detect MMP13 in osteoclasts, other cells of hematopoietic
origin, specifically in the monocyte/macrophage lineage, can
express MMP13 [21]. To distinguish the effects of the Mmp13
mutation on osteoblasts and chondrocytes from its effects on cells
derived from the hematopoietic lineage, we asked whether trans-
plantation of WT bone marrow could rescue the Mmp13
2/2
phenotype. As previously observed in WT hosts [22], we
confirmed that bone marrow was derived from donor mice
(Fig. 5A left panel), while chondrocytes (Fig. 5A, middle panel) and
osteoblasts/osteocytes in the callus (Fig. 5A, right panel) were host
derived. Histology (Fig. 5B) and histomorphometric analyses
(Fig. 5C) showed that there was no difference in the proportion of
cartilage in the callus at 14 days post-fracture, or in the proportion
of bone in the callus at 28 days post-fracture between Mmp13
2/2
mice that received WT (WTRMmp13
2/2) and Mmp13
2/2
(Mmp13
2/2RMmp13
2/2) bone marrow. These results demon-
strate that MMP13-competent hematopoietically derived cells,
including osteoclasts are insufficient to restore the timely re-
sorption of cartilage and bone in Mmp13
2/2 fracture callus. This
suggests that there is an intrinsic defect in chondrocytes,
osteoblasts and/or their matrices as the source of the Mmp13
2/2
healing phenotype.
Mmp13 is required for healing by intramembranous
ossification
To differentiate the consequences of the Mmp13
2/2 mutation on
cartilage and bone during repair, we examined healing via
intramembranous ossification in fractures that were stabilized with
a rigid external fixator [4,5] and in a cortical defect model [23,24].
WT and Mmp13
2/2 mice that received stabilized fractures were
examined at 10 and 28 days post-fracture (Fig. 6A). Unlike the
Mmp9
2/2 mice, which display aberrant cartilage formation at
10 days post-fracture (Fig. 6A bottom left panel; [5]), Mmp13
2/2
stabilized fracture calluses (Fig. 6A, middle left panel) did not
display cartilage and were comparable to WT (Fig. 6A, top left
panel). At 28 days post-fracture, histological analyses suggested
that Mmp13
2/2 stabilized fracture calluses (Fig. 6A, middle right
panel), were larger and contained more bone as compared to WT.
However, since differences in callus sizes and bone content may
result from variability in the alignment of bone ends at the fracture
site, we turned to another model of intramembranous bone
healing for quantification.
During healing of cortical defects in long bones, no cartilage is
formed [23,24]. Healing produces new compact bone to repair the
damaged compact bone as well as spongy bone in the marrow
space underlying the cortical defect. This spongy bone is
eventually remodeled and removed [24,25]. Cortical defects were
produced in WT and Mmp13
2/2 mice and assessed at 21 or
28 days by histology and histomorphometry. SO staining
confirmed that no cartilage was present in the defects at the time
points examined regardless of genotype (data not shown). TC
staining suggested that there was an increased amount of spongy
bone in Mmp13
2/2 mice as compared to WT at 21 and 28 days
post-injury (Fig. 6B). Histomorphometric analyses of these samples
confirmed that while there was no measurable difference in the
ratio of compact bone volume as a proportion of total defect
volume in these defects, there was a significant increase in the ratio
of spongy bone volume as a proportion of defect volume in
Mmp13
2/2 mice as compared to WT at 21 and 28 days post-
surgery (Fig. 6B). These results indicate that the defects observed
during late stages of cortical defect healing are similar to the bone
remodeling defects observed in non-stabilized fractures. Since
cortical defect healing occurs without cartilage intermediates, this
model allowed us to produce a bone phenotype in the absence of
cartilage perturbations. We conclude that the Mmp13
2/2 repair
defect occurring in bone can be uncoupled from the defect
occurring in cartilage; therefore the Mmp13
2/2 mutation overall
affected cartilage and bone remodeling independently of one
another during fracture repair.
DISCUSSION
MMP13 is required for cartilage resorption
We demonstrate here that the absence of MMP13 does not affect
the overall amount of cartilage produced in the callus during non-
stabilized fracture healing, but rather affects the removal of
hypertrophic cartilage from the callus. This is reminiscent of
skeletal development in the absence of MMP13, where an
accumulation of hypertrophic cartilage results from its delayed
Table 1. Mechanical properties of intact tibiae and unstabilized fracture calluses.
..................................................................................................................................................
Healing time (days)
Intact 14 21 28
Moment (N*mm) WT 612.4186236.998 WT 681.5826342.389 WT 470.8506277.999 WT 639.6296344.144
Mmp13
2/2 539.0636215.845 Mmp13
2/2 610.2006458.343 Mmp13
2/2 735.2076454.051 Mmp13
2/2 512.4386268.329
Results are given as mean 6 SD of sample group (intact WT n=10, Mmp13
2/2 n=10; 14 days post fracture WT n=7,Mmp13
2/2 n=5; 21 days WT n=2,Mmp13
2/2
n=7; 28 days WT n=6,Mmp13
2/2 n=2).
doi:10.1371/journal.pone.0001150.t001
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PLoS ONE | www.plosone.org 5 November 2007 | Issue 11 | e1150removal from the endochondral growth plate [9,10]. Our study
has provided evidence for the importance of MMP13 activity
during skeletal repair, which is both complementary to and distinct
from its role during development.
Previous studies have also revealed a mechanistic link between
fetal skeletal development and adult skeletal repair [3,5]. The
delayed cartilage removal in Mmp13
2/2 mice resembles the
phenotype that was observed in Mmp9
2/2mice during develop-
Figure 5. Transplant of WT bone marrow does not rescue the
Mmp13
2/2 non-stabilized fracture healing phenotype. (A) Immunos-
taining for GFP on callus tissues from Mmp13
2/2 mice transplanted with
bone marrow from b-actin GFP mice (GFPRMmp13
2/2 mice) . (Left
panel) Bone marrow cells (bm) are positive for GFP (black staining)
showing they are donor-derived but the adjacent cortex (c) is negative.
(Middle panel) Chondrocytes at day 14 and (Right panel) osteocytes
embedded in the new bone (arrows) at day 28 do not stain for GFP,
showing they are host-derived. (B, Left column) SO and (Right column)
Masson’s Trichrome staining of non-stabilized fracture calluses from
Mmp13
2/2 mice transplanted with WT bone marrow (WT R Mmp13
2/2)
and Mmp13
2/2 mice transplanted with Mmp13
2/2 bone marrow
(Mmp13
2/2 R Mmp13
2/2) show no difference in the amount of
cartilage volume at 14 days post-fracture (WT R Mmp13
2/2 n=6,
Mmp13
2/2R Mmp13
2/2 n=5) and no difference in the amount bone at
day 28 (WT R Mmp13
2/2 n=7, Mmp13
2/2R Mmp13
2/2 n=4). (C)
Histomorphometric analyses of total cartilage volume as a proportion of
total callus volume (CV/TV; day 14) and total bone volume as
a proportion of total callus volume (BV/TV; day 28) demonstrate no
significant difference between WT R Mmp13
2/2 and Mmp13
2/2 R
Mmp13
2/2 animals, suggesting that bone marrow transplant does not
rescue the Mmp13
2/ non-stabilized fracture healing phenotype.
Bonferroni corrected t-test, bars represent means 6 SD. Scale bars: (A,
left and middle)=50 mm, (A, right)=25 mm, B=1 mm.
doi:10.1371/journal.pone.0001150.g005
Figure 6. MMP13 is required for normal healing by intramembranous
ossification. (A, Left column) SO stain of stabilized fracture calluses at day
10 post-fracture show that unlike Mmp9
2/2 mice, no cartilage is formed
during stabilized fracture healing in Mmp13
2/2mice (n=14)comparedto
WT mice (n=3).(A, Right column) At day 28, stabilized fracture calluses in
Mmp13
2/2 mice (n=12) appear to have increased bone volume as
compared to WT (n=14) by histology. (B) Masson’s Trichrome staining of
cortical defect samples at 21 and 28 days post-surgery suggests an
increased amount of bone in Mmp13
2/2mice. Labels designate compact
(Co) and spongy (S) regions of defect. Histomorphometric analyses (within
the boxed area) of WT (d21n=5,d28n=6)andMmp13
2/2 (d21 n=6,d28
n=6) cortical defect samples confirm that there is an increase in spongy
bonevolume(SV/DV)butnot compactvolume(CoV/DV)inthedefectarea
measured at day 21 and 28 (*p,0.05) in Mmp13
2/2 as compared to WT.
Bonferroni corrected t-test, bars represent means 6 SD. Scale bars:
A=1 mm, B=500 mM.
doi:10.1371/journal.pone.0001150.g006
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PLoS ONE | www.plosone.org 6 November 2007 | Issue 11 | e1150ment and repair of long bones [5,8]. While MMP9 is strongly
expressed by osteoclasts in the fracture callus, we observed that
MMP13 was confined to chondrocytes and osteoblasts, suggesting
that the Mmp13
2/2 and Mmp9
2/2 phenotypes may differ at the
cellular level. Further analyses of these phenotypes confirmed this
assumption. While both angiogenesis and osteoclast recruitment,
two events essential for proper and timely resorption of
endochondral cartilage during healing are delayed in Mmp9
2/2
calluses [5,8,15,26,27], in contrast, there was no disruption in the
recruitment of mature osteoclasts or blood vessels in Mmp13
2/2
fracture calluses. However, consistent with our observations,
providing a source of WT osteoclasts by bone marrow transplant
did not rescue the Mmp13
2/2 repair phenotype. This is distinct
from the Mmp9
2/2 phenotype where the delay in cartilage
resorption during fetal bone development was rescued by trans-
plant of WT bone marrow [8]. In addition, the Mmp9
2/2 fracture
phenotype could be rescued by exogenous VEGF, which
stimulated the invasion of the callus by blood vessels and
osteoclasts [5]. These results suggest a role for MMP13 prior to
vascular invasion and osteoclast recruitment in the process of
hypertrophic cartilage remodeling (Fig. 7). The observed decrease
in aggrecan cleavage in the absence of MMP13 activity suggests
impaired degradation of the cartilage ECM, which slowly resolves
over time, in Mmp13
2/2 mice. Thus, MMP13 produced by
hypertrophic chondrocytes appears to be directly involved in the
initiation of hypertrophic cartilage degradation, independent from
MMP9 and the recruitment of matrix resorbing cells and blood
vessels.
MMP13 is required in bone remodeling
We found other differences between Mmp13
2/2 and Mmp9
2/2
phenotypes when we analyzed the production and remodeling of
new bone in the fracture callus. In Mmp9
2/2 mice, the delayed
removal of hypertrophic cartilage correlated with a delay in
ossification. On the contrary, Mmp13
2/2 mice did not exhibit
a delay in the deposition of new bone as a consequence of the
cartilage phenotype. Instead, we observed an increase in bone
volume at later stages of healing. This increase was restricted to
the areas of spongy bone, much like those observed in Mmp13
2/2
bones during development [10]. Since spongy bone is lower in
density and strength than compact bone, this result may explain
why no significant difference was detected when we compared the
strength of WT and Mmp13
2/2calluses at late stages of healing.
Examination of stabilized fractures and cortical defects also
revealed a role for MMP13 in the timely resorption of the transient
compartments of spongy bone during healing via intramembra-
nous ossification. Unlike development, where MMP13 activity is
required for the formation of endochondral but not intramem-
branous bone, these observations suggest that its proteolytic
activity is required during repair regardless of the type of
ossification involved. These results support the idea that the bone
defect observed during adult skeletal repair in the absence of
MMP13 is caused by a defect intrinsic to osteoblasts or the matrix
they produce. Furthermore, WT osteoclasts did not accelerate the
resorption of spongy bone in the Mmp13
2/2callus. Similar to its
role in hypertrophic cartilage, MMP13 present in new bone
matrix may be required for the initial degradation of ECM
components allowing the timely remodeling of the bone callus
(Fig. 7).
Cartilage-bone interaction in the Mmp13
2/2
fracture callus
That bone remodeling was delayed in both intramembranous and
endochondral ossification during bone repair demonstrates that in
the absence of MMP13 the cartilage phenotype manifests
independently of the bone phenotype. These results are in
accordance with the observations reported for skeletal develop-
ment in the absence of MMP13 by Stickens et al. (2004). In
addition, the observed delay in cartilage resorption did not affect
the deposition of bone in the Mmp13
2/2 callus at day 14 post-
fracture. While bone and cartilage have been shown to provide
regulatory feedback to each other [28], these results indicate that
proper remodeling of the ECM depends on unique signals or
properties intrinsic to the bone and cartilage.
Regulatory interactions between bone and cartilage also take
place during the early stages of fracture healing [5]. During the
early stages of non-stabilized fracture healing in the absence of
MMP13, we observed a delay in initial bone deposition correlated
with an increase in cartilage formation. This might indicate
a transient inhibition of osteogenesis due to increased chondro-
genesis or a decreased ability of MMP13-deficient mesenchymal
precursor cells to differentiate into fully mature osteoblasts [29].
This early imbalance was not observed during stabilized fracture
healing in either WT or Mmp13
2/2 mice, which healed via
intramembranous ossification. This stands in contrast with
Mmp9
2/2 mice that heal stabilized fractures via an aberrant
endochondral process [5].
A role for MMP13 in osteoclasts?
The independent manifestation of the cartilage and bone
phenotypes may be due to the fact that osteoclasts are not affected
in Mmp13
2/2 mice. Several studies point to MMPs, possibly even
MMP13, as potentially important mediators of osteoclast re-
cruitment during development and repair [30–33] and a number
of factors that promote bone resorption/remodeling are able to
affect Mmp13 gene expression [34–38]. Our results indicate that
Mmp13 is not co-expressed with Mmp9 in osteoclasts. Furthermore,
our bone marrow transplantation studies indicate that WT
osteoclasts were not able to support normal ECM remodeling in
the Mmp13
2/2 environment, suggesting that they did not provide
Figure 7. A model for MMP13 action in the cartilage and bone
compartments of the non-stabilized fracture callus. MMP13 secreted
from hypertrophic chondrocytes (HC) and osteoblasts (OB) acts upon
the ECM to produce a pre-processed ECM in both compartments. This
pre-processed ECM is then invaded by blood vessels and further
modified by osteoclasts (OC) secreting MMP9, leading to the pro-
duction of a processed ECM. This processed ECM then promotes further
steps of callus maturation including hypertrophic chondrocyte apo-
ptosis, replacement of cartilage by bone and new bone remodeling.
doi:10.1371/journal.pone.0001150.g007
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intrinsic to the ECM. MMP13 activity may be required prior to
the onset of osteoclastic and MMP9 activity to prepare the bone
matrix for resorption (Fig. 7). Indeed, prior work has suggested
that MMP13 does participate in the resorption of the organic bone
matrix, but that this is through the action of mesenchymal stem
cell-derived cells, not osteoclasts [39]. Consequently, WT (and
therefore MMP13-competent) osteoclasts are unable to perform
their normal function due to a deficiency in this preparatory step
in the Mmp13
2/2 ECM.
Implications for normal skeletal repair
In humans, although the mode of healing may vary depending on
the site of injury, extent of trauma, and fixation, most fractures
heal through endochondral ossification. Therefore in the majority
of clinical cases, remodeling of both cartilage and bone is critical
for bone bridging and full recovery of mechanical integrity. While
most fractures heal spontaneously, 5 to 10% fail to heal in a timely
manner [40]. Risk factors such as age, injury type and socio-
economic conditions have been shown to impact the outcome of
healing, yet little is known about the genetic predispositions to
impaired healing. Although mutations in MMP genes have been
linked to skeletal defects in humans [12,41], none have been
associated with delayed healing. Our results show that MMP13
and other MMPs such as MMP9 play a role in all stages of fracture
healing from the early deposition of cartilage and bone to the late
stages of callus remodeling. Perturbations in any of these processes
may compromise healing. Although Mmp13
2/2 mice have
phenotypic manifestations similar to Mmp9
2/2 mutants, such as
late onset of hypertrophic cartilage removal, we show that there
are intrinsic differences in the way these two proteases act in
fracture repair and that treatment strategies to overcome these
defects differ. These observations point to the need for a better
understanding of the underlying causes of delayed healing in
humans in order to plan efficient therapies. From this perspective,
the detailed analyses of Mmp9
2/2 and Mmp13
2/2mutant mice
shed light into the normal process of bone healing and potential
approaches to treat impaired healing.
MATERIALS AND METHODS
Non-stabilized and stabilized fractures
Mmp13
2/2 mice (3- to 6-month-old males; 30–35 grams (g)) and
their WT littermates were anesthetized with an intraperitoneal
injection of 50 mg/ml Ketamine/0.5 mg/ml Medetomidine
(0.03 ml/mouse). Closed, standardized non-stabilized fractures
were produced as previously described [5]. For stabilized fractures,
an external fixator was placed as previously described [4]. Mice
were sacrificed by cervical dislocation following an intraperitoneal
injection of 2% Avertin (0.5 ml/mouse). Non-stabilized fractures
were collected at 5, 10, 14, 21, 28, and 56 days post-fracture.
Stabilized fractures were collected at 10 and 28 days post-fracture.
All protocols were approved by the Institutional Animal Care and
Use Committee at UCSF.
Bone marrow transplantation
10-week-old male Mmp13
2/2 mice were lethally irradiated with
two 6 Gy doses of c-irradiation 3–4 hours apart. Bone marrow
cells from WT, Mmp13
2/2 and b-actin Green Fluorescent Protein (GFP)
mice were transplanted into irradiated Mmp13
2/2 mice from the
same FVB/N background as previously described (Colnot et al.,
2006). Following a recovery period (Colnot et al. 2006), non-
stabilized fractures were produced in chimeric mice as described
above. Fracture tissues were collected at 14 and 28 days post-
fracture and processed for histological analyses.
Cortical defects
Monocortical defects (1mm in diameter) were produced on the
anterior-proximal tibia as previously described [23,24]. Samples
were collected at 21 and 28 days post-surgery and processed for
paraffin embedding. Longitudinal sections parallel to the plane of
the defect were collected and processed for histological analyses.
Histology and immunohistochemistry
Callus tissues were fixed overnight at 4uC in 4% paraformalde-
hyde, decalcified at 4uC in 19% EDTA (pH 7.4) for 10–14 days,
then dehydrated in a graded ethanol series and embedded in
paraffin. Sections (10 mm thick) were stained with Safranin-O/
Fast Green (SO) to detect cartilage formation as described [4]. A
modified Milligan’s Trichrome (TC) staining using Analine Blue
was performed to analyze bone formation in the fracture callus.
Tartrate-resistant acid phosphatase (TRAP) staining was per-
formed using a leukocyte acid phosphatase kit (Sigma, St. Louis,
MO) as previously described [16]. Immunohistochemistry for
platelet endothelial cell adhesion molecule-1 (PECAM) was done
as previously described [5,8]. Immunohistochemistry for the
DIPEN epitope was performed as described previously [10].
Calluses collected from Mmp13
2/2 mice transplanted with bone
marrow from b-actin GFP mice were fixed and decalcified as
mentioned above, then cryo-embedded in OCT. Sections (8 mm)
were cut on a cryostat (Leica). For GFP immunostaining,
cryosections were treated with 0.3%H2O2 in methanol, digested
with ficin (Zymed), and blocked with 5% milk in PBS and 5%
normal goat serum in PBS. Antibody staining was done using
rabbit anti-GFP antibody (Abcam) followed by goat anti-rabbit
secondary antibody conjugated to horseradish peroxidase. Slides
were developed with diaminobenzidine and counterstained with
0.1% fast green.
In situ hybridization
In situ hybridization was performed using
35S-labeled probes from
mouse cDNAs for Mmp13, Col1 a1 chain (Col1a1 – Mouse Genome
Informatics), Mmp9, Col10 (Col10a1 – Mouse Genome Informat-
ics), Vegf (Vegfa – Mouse Genome Informatics), Oc (Tcirg1 – Mouse
Genome Informatics) and Col2 (Col2a1 – Mouse Genome
Informatics) as previously described [16]. Emulsion coating and
image analyses were performed as described previously [2,42].
Histomorphometric measurements
Histomorphometry on fracture samples was performed as pre-
viously described [5,43]. To determine the amount of cartilage
within each callus, every thirtieth section (300 mm) was stained
with SO. Adobe Photohsop was used to capture images from
a Leica DM 5000 B light microscope (Leica Microsystems GmbH,
Wetzler, Germany) that was equipped with a camera (Diagnostic
Instruments, Inc., Sterling Heights, MI). To determine the amount
of bone within each callus, adjacent sections were stained with TC
and photographed. The area of the callus, cartilage and bone
(including compact and spongy bone [44] was determined using
Adobe PhotoShop.
To determine the amount of bone within cortical defects, 2
central sections within the defect were selected and stained with
TC. In Adobe PhotoShop, a standard box (as shown in Figure 6)
was used to select an area in the center of the defect, including the
damaged cortical region and the underlying bone marrow space.
The total area of bone within the defect, as well as the areas of
MMP13 in Skeletal Repair
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were quantified and the ratios of compact repair/defect volume
and spongy repair/defect volume were calculated.
Mechanical testing
Mechanical testing was performed on intact tibiae from 12-week-
old mice and tibiae from mice that had received non-stabilized
fractures collected at 14, 21 and 28 days post-fracture. The
proximal and distal end of each tibia was potted in a cryovial cap
(Corning Incorporated Life Sciences, Lowell, MA) in polymethyl-
methacrylate (PMMA) bone cement at room temperature. Potted
samples were stored overnight at 4uC until testing [45]. Prior to
testing, samples were warmed to room temperature for at least
30 minutes; any intact fibulae were removed and mineral-free PBS
was applied to the calluses after mounting into the testing
apparatus. Tests were performed at room temperature. Data
was collected using LabView4 (National Instruments Corporation,
Austin, TX).
Each potted mouse tibia specimen was placed horizontally into
a uniaxial test frame to prevent gravitational loading of the
specimen by the PMMA endcaps [46]. The distal end of the
specimen was rigidly held to the test frame while the proximal end
was attached to a single-cable pulley system. Movement of the test
frame actuator caused tension in the cable, which was positioned
around a loading ring so as to generate a pure moment, or couple,
loading condition. A uniaxial load cell (Sensotec Model 129, 25 lb
capacity, Honeywell International, Inc., Columbus, OH) was used
to monitor cable tension, and the moment applied to the specimen
was calculated as the product of the cable tension and the diameter
of the loading ring (N*mm). Moment and crosshead displacement
were monitored, and the ultimate moment over the entire
destructive test cycle was recorded as the failure strength of the
specimen.
Statistical analyses
For non-stabilized fracture studies, Wilcoxon rank sum tests were
used at each timepoint to examine whether differences between
WT and Mmp13
2/2 samples in cartilage, callus, and bone
volumes were statistically significant (a,0.05). Bonferroni adjust-
ments were performed. For mechanical testing of non-stabilized
fracture calluses, force data were analyzed using GraphPad Prism
4 by one-way analysis of variance (ANOVA). For bone marrow
transplant and cortical defect studies, histomorphometry data were
analyzed using ANOVA followed by Bonferroni corrected t-tests
for data sets where ANOVA, p,0.05.
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